---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-24-000061"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:38:40.971333+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Curis Q2 net loss $11.8M; emavusertib gets EU ODD for PCNSL

## Summary
- Net loss of $11.8M ($2.03/sh) vs $12.0M ($2.47) in Q2 2023; revenue $2.5M from Erivedge royalties.
- Cash, equivalents and investments $28.4M; expected to fund operations into Q1 2025.
- EC granted Orphan Drug Designation to emavusertib for treatment of primary CNS lymphoma.
- Initial data for 15-20 R/R PCNSL patients expected late 2024; ASH presentation planned.
- Updated TakeAim Leukemia data and frontline triplet combo safety data due late 2024.

## SEC filing metadata
- accession: 0001108205-24-000061
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000061/0001108205-24-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000061/cris-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-24-000061
- JSON: https://secwatch.observer/filing/0001108205-24-000061.json
- Plain text: https://secwatch.observer/filing/0001108205-24-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.